Business Wire

IQM Quantum Computers Unveils Development Roadmap Focused on Fault-tolerant Quantum Computing by 2030

Share

IQM Quantum Computers (IQM), a global leader in superconducting quantum computing, today announced its development roadmap with technical milestones targeting fault tolerant quantum computing by 2030, while enabling a dedicated Noisy Intermediate-Scale Quantum (NISQ) approach for near-term usage.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113963297/en/

IQM Quantum Computers Development Roadmap (Graphic: Business Wire)

Since its start, IQM has successfully delivered full-stack quantum computers based on its first three processor generations. IQM's 12-year roadmap reflects its vision for pioneering quantum solutions through novel algorithmic approaches, modular software integration, and scalable hardware advancements. It leverages the company's ability to design and fabricate next-generation quantum processors with seamless integration into full-stack systems controlled by an open software stack.

IQM's unique co-design capabilities steer the roadmap towards efficient error-correction implementations with high system performance by merging IQM's two processor topologies IQM Star and IQM Crystal. To enable the roadmap, IQM systematically invests in its R&D, testing and fabrication facilities to boost technology scaling up to 1 million qubits while maintaining high qubit quality and gate fidelity.

To support the developer community and to ease the usage of quantum computing, IQM will also enable tight high-performance computing (HPC) integration and create a special software development kit (SDK). Open interfaces will empower the ecosystem, including quantum error mitigation, co-develop libraries and use-cases on IQM’s quantum computers.

The company aims to achieve quantum advantage across multiple industry domains, focusing on quantum simulations, optimization, and quantum machine learning. According to a McKinsey report, these selected use-cases will unlock a value potential of more than US$28 billion by 2035.

Quantum advantage will be provided by fully error-corrected systems with hundreds to thousands of high-precision logical qubits, for which error correction will be enabled by efficiently implementing novel quantum low-density parity-check (QLDPC) codes. This approach reduces the hardware overhead by a factor of up to 10 compared to surface code implementation.

Furthermore, IQM is targeting high-precision logical qubits with error rates below 10^-7, enabling quantum advantage for applications demanding exceptional accuracy, such as in chemistry and materials science.

“We are implementing Quantum low-density parity-check (QLDPC) codes through a novel chip topology, enabled by our uniquely connected Star topology, long-distance couplers and a very compact approach for advanced packaging and signal routing,” said Dr. Jan Goetz, Co-Founder and Co-CEO of IQM Quantum Computers. “This underlines our commitment to hardware efficiency, enabling a feasible and scalable pathway to fault tolerance combined with an open and modular software architecture.”

Goetz emphasizes that the company’s proprietary cleanroom facilities will support the fabrication of complex processors with unique long-range connections, facilitating high-performance quantum processors.

To this end, IQM will implement novel solutions for advanced packaging and 3D integration to ensure scalability while maintaining its ambitious goals to reduce error rates, while its large-scale processors will be built up in a modular way and powered by cryogenic electronics. The results are reduced heat load, strongly miniaturized packaging solutions, and reduced cost per qubit. These features will result in more performant and affordable products for IQM's customers in the HPC and enterprise market.

Offering on-premises and cloud access, IQM has been specializing in integrating quantum systems into HPC centers since 2020. The latest is Germany’s first hybrid quantum computer at the Leibniz Supercomputing Centre.​

IQM aims to explain further details of the roadmap in future publications, blog posts, and at industry and academic events.

About IQM Quantum Computers:

IQM is a global leader in designing, building, and selling superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers anywhere in the world. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 280 employees with offices in Espoo, Madrid, Munich, Paris, Palo Alto, Singapore and Warsaw.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113963297/en/

Contacts

Email: press@meetiqm.com
Mobile: +358504790845
www.meetiqm.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.meetiqm.co
m%2F&esheet=54152085&newsitemid=20241113963297&lan=en-US&anchor=www.meetiqm.com&
index=2&md5=0e164a7e428807f4e256044fee302953

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release

Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient

Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release

Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b

Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release

Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release

BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release

Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye